Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Consumer Self-Care Products, announced today that it has completed the previously announced sale of its Generic Rx Pharmaceuticals business to Altaris Capital Partners, LLC for $1.55 billion, with customary adjustments, completing Perrigo's transformation to a global consumer self-care company.

Perrigo CEO and President Murray S. Kessler commented, "Closing this transaction was another important milestone for Perrigo's transformation. We are now a leading pure-play global consumer self-care company that has significant resources to invest and has a passionate and committed team that is dedicated to making our vision a reality - To make lives better by bringing quality affordable self-care products consumers trust, everywhere they are sold. I am more excited than ever about the company's future."

Kessler concluded, "I would like to thank the Rx team for their dedication throughout this process and I am confident that they will continue to be successful in their mission of developing, manufacturing and distributing high quality, affordable healthcare products."

About Perrigo

Perrigo Company plc (NYSE; TASE: PRGO) is a leading provider of Quality, Affordable Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Led by its consumer self-care strategy, Perrigo is the largest store brand OTC player in the U.S. in the categories in which it competes through more than 9,000 SKUs under customer 'own brand' labels. Additionally, Perrigo is a Top 10 OTC company by revenue in Europe, where it markets more than 200 branded OTC products throughout 28 countries.